McGill University and Lady Davis Research Institute, Canada
Cancer & Metabolism welcomes studies on all aspects of the relationship between cancer and metabolism, including:
- Molecular biology and genetics of cancer metabolism
- Whole-body metabolism, including diabetes and obesity, in relation to cancer
- Metabolomics in relation to cancer
- Metabolism-based imaging
- Preclinical and clinical studies of metabolism-related cancer therapies
Dr Michael N. Pollak is an internationally recognised expert in cancer endocrinology at the Lady Davis Institute for Medical Research of McGill University and a clinical oncologist at the Jewish General Hospital, Quebec, Canada.
"Cancer & Metabolism will provide a forum for rapid dissemination of research findings concerning metabolic factors that influence cancer risk and cancer pathophysiology, and cancer treatment. The scope of the Journal will allow for an interdisciplinary readership including cancer biologists, endocrinologists, oncologists, clinical trialists and population scientists."
Dr Michael N. Pollak is an internationally recognised expert in cancer endocrinology at the Lady Davis Institute for Medical Research of McGill University and a clinical oncologist at the Jewish General Hospital, Quebec, Canada. His research focuses on the roles of insulin and insulin-like growth factors in cancer biology and he has been the principal investigator on several pivotal clinical trials of new drugs.
His laboratory uses a variety of in vitro and in vivo methods to explore the influences of hormones on cancer behaviour and on cancer risk. In a landmark study published in 1998, Dr. Pollak showed that high levels of Insulin-like Growth Factor-I (IGF-I) are associated with increased the risk of prostate cancer. Since then, his lab have demonstrated that a subset of cancers are dependent on IGF stimulation, and have shown that novel compounds that target IGF bioactivity deserve evaluation as cancer therapies. He is also examining the mechanisms by which the well-known anti-diabetic drug metformin may act to restrain cancer growth or prevent the development of cancer. His laboratory is frequently called upon to act as a reference for the measurement of hormones suspected of being related to cancer biology.
Dr Pollak holds the Alexander Goldfarb Research Chair in cancer research at McGill University, Montreal, Canada, and directs the Division of Cancer Prevention of the Department of Oncology. He practices medical oncology at the Jewish General Hospital in Montreal, and also runs a research lab at the Lady Davis Research Institute, which is affiliated with the Hospital and McGill. He received one of Quebec’s top scientific honors, the Chercheur national award from the Fonds de Recherche Santé Quebec and has published more than 300 research papers.